Dose –response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Conclusions/interpretationSurvodutide reduced HbA1c levels and bodyweight after 16 weeks ’ treatment in participants with type 2 diabetes. Dose-related gastrointestinal AEs could be mitigated with slower dose escalations.Trial registrationClinicalTrials.gov NCT04153929 and EudraCT 2019-002390-60.FundingBoehringer Ingelheim Pharma GmbH& Co. KG, Ingelheim, Germany.Graphical Abstract
Source: Diabetologia - Category: Endocrinology Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Gastroenterology | Germany Health | Metformin | Pharmaceuticals | Study